Methods for enhancing hematopoietic stem/progenitor cell engraftment

Patent metadata

Field	Value
Publication number	US-9737567-B2
Application number	US-201514691870-A
Country	US
Kind code	B2
Filing date	Apr 21, 2015
Priority date	Feb 3, 2009
Publication date	Aug 22, 2017
Grant date	Aug 22, 2017

Abstract

Described herein are methods for enhancing engraftment of hematopoietic stem and progenitor cells using farnesyl compounds identified using a zebrafish model of hematopoietic cell engraftment. The compounds can be used to treat hematopoietic stem cells ex vivo prior to transplantation of the cells. Alternatively, the compounds can be administered to an individual undergoing cell transplantation.

First claim

The invention claimed is:

1. A method for enhancing hematopoietic cell engraftment in a subject following hematopoietic cell transplantation, the method comprising: administering to a subject following hematopoietic cell transplantation a therapeutically effective amount of a compound selected from the group consisting of: S-farnesyl-L-cysteine methyl ester (FCME), and farnesylthioacetic acid (FTA),
wherein the level of engraftment of said hematopoietic cells in said subject treated with S-farnesyl-L-cysteine methyl ester (FCME), and/or farnesylthioacetic acid (FTA) is increased compared to engraftment of a population of hematopoietic cells in an untreated subject.

2. The method of claim 1 , wherein the compound is S-farnesyl-L-cysteine methyl ester (FCME).

3. The method of claim 1 , wherein the compound is farnesylthioacetic acid (FTA).

4. The method of claim 1 , wherein the hematopoietic cells are derived from cord blood.

5. The method of claim 1 , wherein the hematopoietic cells are derived from bone marrow.

6. The method of claim 1 , wherein the hematopoietic cells are derived from blood.

7. The method of claim 1 , wherein the hematopoietic cells are isolated cells.

8. The method of claim 1 , wherein the hematopoietic cells are a heterogeneous or homogeneous population of cells.

9. The method of claim 1 , wherein said subject is a human subject.

10. The method of claim 1 , wherein said hematopoietic cells are hematopoietic stem cells.

11. The method of claim 1 , wherein said hematopoietic cells are hematopoietic progenitor cells.

12. A method for enhancing hematopoietic cell engraftment in a subject, the method comprising:
(a) contacting a population of hematopoietic cells with a compound selected from the group consisting of: 2-chloro-5-farnesylaminobenzoic acid (NFCB), (farnesylthio)propanoic acid (FTP), and farnesyl acetate; and
(b) administering treated cells from step (a) to a subject in need thereof,
wherein the engraftment of said hematopoietic cells treated with said compound is increased compared to engraftment of a population of untreated hematopoietic cells.

13. The method of claim 12 , wherein said population of hematopoietic cells is derived from cord blood.

14. The method of claim 12 , wherein said population of hematopoietic cells is derived from bone marrow or from blood.

15. The method of claim 12 , wherein said population of hematopoietic cells are isolated cells.

16. The method of claim 12 , wherein said population of hematopoietic cells is a heterogeneous or homogeneous population of cells.

17. The method of claim 12 , wherein said contacting step is performed on ex vivo cells in culture.

18. The method of claim 12 , wherein said subject is a human subject.

19. The method of claim 12 , wherein said hematopoietic cells are hematopoietic stem cells or are hematopoietic progenitor cells.

Assignees

• Children'S Medical Center Corp

Inventors

• Zon Leonard I
• Li Pulin

Classifications

• A61K31/255

  of sulfoxy acids or sulfur analogues thereof · CPC title

• A61K2035/124

  the cells being hematopoietic, bone marrow derived or blood cells · CPC title

• A61K31/221 Primary

  with compounds having an amino group, e.g. acetylcholine, acetylcarnitine · CPC title

• A61K35/28 Primary

  Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells · CPC title

• C12N5/0647

  Haematopoietic stem cells; Uncommitted or multipotent progenitors · CPC title